A multicenter, open, long term safety study of 52 weeks treatment with vildagliptin (100 mg qd) in patients with type 2 diabetes (extension study of study CLAF237A1303)

Trial Profile

A multicenter, open, long term safety study of 52 weeks treatment with vildagliptin (100 mg qd) in patients with type 2 diabetes (extension study of study CLAF237A1303)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 24 Mar 2008 Status changed from in progress to completed on clinicaltrials.gov.
    • 25 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top